The fund lagged the S&P 500 and Russell 1000 Value Index in Q2 2026, returning 3.87% before exiting BIO.
Longleaf Partners Fund posted a 3.87% return in Q2 2026, trailing the S&P 500’s 15.20% gain and the Russell 1000 Value Index’s 13.87% advance. The underperformance prompted portfolio adjustments, including the exit of its Bio-Rad (NYSE: BIO) position.
The fund initiated one new healthcare holding during the quarter but did not disclose further details. Prior periods saw mixed relative performance, with Q2 2026 marking a notable deviation from broader market benchmarks.
No immediate market reaction was reported following the disclosure.